to characterize the prevalence of transmitted drug resistance mutations (TDRMs) by plasma analysis of 750 patients at the time of HIV diagnosis from January 1, 2013 to November, 16, 2016 in the Veneto region (Italy), where all drugs included in the recommended first line therapies were prescribed, included integrase strand transfer inhibitors (InNSTI).

Andreis, S., Basso, M., Scaggiante, R., Cruciani, M., Ferretto, R., Manfrin, V., et al. (2017). Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: impact on susceptibility to first-line strategies including Integrase strand-transfer inhibitors. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 10, 106-112 [10.1016/j.jgar.2017.05.011].

Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: impact on susceptibility to first-line strategies including Integrase strand-transfer inhibitors

SARMATI, LOREDANA;ANDREONI, MASSIMO;
2017-07-18

Abstract

to characterize the prevalence of transmitted drug resistance mutations (TDRMs) by plasma analysis of 750 patients at the time of HIV diagnosis from January 1, 2013 to November, 16, 2016 in the Veneto region (Italy), where all drugs included in the recommended first line therapies were prescribed, included integrase strand transfer inhibitors (InNSTI).
18-lug-2017
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/17 - MALATTIE INFETTIVE
English
Con Impact Factor ISI
Integrase strand transfer inhibitors; chronic HIV infection; primary-recent; transmitted drug resistance mutations
Andreis, S., Basso, M., Scaggiante, R., Cruciani, M., Ferretto, R., Manfrin, V., et al. (2017). Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: impact on susceptibility to first-line strategies including Integrase strand-transfer inhibitors. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 10, 106-112 [10.1016/j.jgar.2017.05.011].
Andreis, S; Basso, M; Scaggiante, R; Cruciani, M; Ferretto, R; Manfrin, V; Panese, S; Rossi, M; Francavilla, E; Boldrin, C; Alvarez, M; Dal Bello, F; Mengoli, C; Turriziani, O; Sarmati, L; Antonelli, G; Andreoni, M; Palu, G; Parisi, S
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/186941
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 17
social impact